Identification of Lifelines participants at high risk for development of rheumatoid arthritis

Arends, Suzanne; Trouw, Leendert A.; Toes, René E. M.; Zanten, A. van; Roozendaal, Caroline; Limburg, P. C.; Bootsma, Hendrika; Brouwer, Elisabeth

doi:10.1136/annrheumdis-2017-211256

Cited by 2 publications

(1 citation statement)

References 10 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These may be considered 'population-based' and include studies of populations who are at-risk for RA such as North American indigenous populations who have high prevalence rates of RA [5,6], and studies of first-degree relatives of individuals with clinical RA [7,9]. There are also studies which have identified individuals at-risk for future RA through approaches such as ACPA testing in health-fairs [16 & ] or population surveys [32].…”

Section: How Are Individuals Identified Who Are At-risk For Future Rh...mentioning

confidence: 99%

Rheumatoid arthritis: prediction of future clinically-apparent disease, and prevention

Deane

2024

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review This review discusses updates in the prediction and prevention of future rheumatoid arthritis (RA). Recent findings In individuals with musculoskeletal symptoms and elevated antibodies to citrullinated proteins (ACPA) without clinical inflammatory arthritis (IA), a ‘simple’ score has a positive predictive value (PPV) of ∼28% for clinical IA/RA within 1 year, and a comprehensive score (including ultrasound) has a PPV of ∼71% for clinical RA within 5 years. Controlled clinical trials in individuals at-risk for future RA have been performed using corticosteroids, rituximab, atorvastatin, methotrexate, hydroxychloroquine and abatacept. Abatacept modestly reduced rates of incident clinical RA and imaging inflammation within the trials, rituximab delayed clinical IA, and methotrexate improved function, symptoms and imaging inflammation. Vitamin D with or without omega 3 fatty acids reduced incidence of autoimmune diseases, including RA. While not proven in controlled clinical trials, observational studies suggest exercise, weight loss and smoking cessation may reduce progression to clinical RA. Summary Prediction and prevention of RA is advancing although there are no currently approved interventions for prevention. Future studies should include deeper evaluation of the pathophysiology of RA development to improve prediction and identify key pathways to target in future clinical trials, as well as develop infrastructure to support prevention-related research.

show abstract

Section: How Are Individuals Identified Who Are At-risk For Future Rh...mentioning

confidence: 99%

Rheumatoid arthritis: prediction of future clinically-apparent disease, and prevention

Deane

2024

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

Pre-RA: Can early diagnosis lead to prevention?

Haville

Deane

2022

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

Identification of Lifelines participants at high risk for development of rheumatoid arthritis

Cited by 2 publications

References 10 publications

Rheumatoid arthritis: prediction of future clinically-apparent disease, and prevention

Rheumatoid arthritis: prediction of future clinically-apparent disease, and prevention

Pre-RA: Can early diagnosis lead to prevention?

Contact Info

Product

Resources

About